Ambrosus partners with TREKtx to apply blockchain for pharmaceutical mfg monitoring

Ambrosus, a blockchain-based ecosystem for the supply chain today announced a partnership with pharmaceutical company Trek Therapeutics to apply integrated sensors coupled with blockchain-based technology to pharmaceutical drug manufacturing in Trek’s clinical development program.
Combining high-tech sensors, blockchain, and powered by smart contracts, Ambrosus is building the world’s first publicly-verifiable, community-driven ecosystem to ensure the quality, safety, and origins of essential products, such as medicine, food, and commodities.
As part of the collaboration, Ambrosus will conduct pilot projects with Trek to monitor the quality, safety, and integrity of all stages of the pharmaceutical manufacturing process.
Trek Co-founder and CEO Dr. Ann Kwong said:

“Currently the pharmaceutical manufacturing process is highly regulated by pharmaceutical manufacturers and by regulatory authorities in an extremely labor-intensive and expensive manner. We hope to partner with Ambrosus to create a continuous monitoring and tracking system that will be less labor intensive, less expensive, and more transparent to all parties with a stake in quality pharmaceutical manufacturing.”
“Our goal is to develop a system that is robust enough that Trek can submit data to support our manufacturing application for regulatory approval of our drugs from the FDA and EMA authorities. Additionally, patients currently have no way to ascertain the quality of the medicines they ingest. Trek believes it is important to be able to demonstrate to patients that while our drugs are affordable, they’re also of the highest quality.”
“Backed by a superb core team of developers, advisors, and researchers, Ambrosus’ protocol will provide the transparency necessary in our manufacturing process to help ensure the integrity of supply chains. With our commitment to providing affordable high-quality medicine, we believe this partnership could revolutionize the pharmaceutical industry quality control of manufacturing at every stage from plant to patient.”

Based at two innovation hotspots in Switzerland (EPFL Innovation Park in Lausanne and Crypto Valley in Zug), Ambrosus boasts an experienced, global team and an advisory board containing some of the world’s best thinkers and doers in the areas of food quality, sensor technology, and blockchain/smart contracts.

Angel Versetti, Ambrosus CEO

Ambrosus Co-Founder and CEO Angel Versetti said:

“Following the successful implementation of the Ambrosus protocol in global food supply chains, we are delighted to now apply our blockchain protocol to help ensure the quality, safety, and integrity of another vitally important product – pharmaceuticals.”
“Trek is focused on developing safe, novel medicines for infectious diseases at affordable and accessible prices. The pharmaceutical supply chain encompasses many phases and a multitude of stakeholders, requiring responsible parties to seek new methods of guaranteeing the quality and integrity of critical products. As Trek continues their mission to develop pharmaceuticals for budget-constrained patients across North America and Europe, our partnership will help to develop protocols to provide transparency and quality assurance during each phase of the process.”

As part of the pilot projects, Ambrosus’s protocol will work to verify and track the entire manufacturing chain from the primary chemical starting materials through multiple steps of synthesis, purification, and verification of the active pharmaceutical ingredient (API); followed by formulation of the API into drug product; packaging, labeling, storage, and shipping to clinical trial sites.
It was also announced that blockchain expert Jaron Lukasiewicz will be joining the Ambrosus team as an advisor, he stated:

“I am excited about the future of the Ambrosus project and equally the team behind it, who together carries decades of experience in their target markets. Ambrosus can become a fundamental technology utilized in sectors ranging from food to pharma, stretching the boundaries of what blockchain technology can accomplish in real world applications.”

Jaron Lukasiewicz has been a notable bitcoin and blockchain industry figurehead since 2012. Lukasiewicz founded and served as CEO of Coinsetter, a New York City-based bitcoin exchange, which was acquired by Kraken in January 2016. The sale was at the time, the largest M&A deal in bitcoin history. Lukasiewicz also served as CEO of Cavirtex, the oldest and largest Canadian bitcoin exchange, which was also acquired by Kraken. Since the acquisition, Lukasiewicz has served as an active advisor to several blockchain companies and blockchain investment funds in addition to his role as the CEO of WRKFLOW.

Exit mobile version